![](https://investorshub.advfn.com/uicon/25182.png?cb=1576664963)
Monday, March 24, 2014 2:07:07 PM
Multicell Immunotheraupeutics is a private company listed as a subsidiary of MCET. It was once Astral. MCET acquired it and it's
patents back in 2007 I believe. (Don't hold me to that). The directors are the same as MCET.
Among the patents were MCT465, 475 and 485. (They were designated something else at the time). By keeping this subsidiary private. Multicell can control it's fate on a takeover attempt by holding the prize hostage.
Also, they could acquire the stock of MCET and not have to declare 10% ownership. Doesn't take too many 9.99% owners to amass
more that 50% of a companies stock. At these prices, a couple of million would do the trick.
JMHO -
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM